Serum platelet-derived growth factor and fibroblast growth factor in patients with benign and malignant ovarian tumors

Anticancer Research

Volumn 32, Issue 9, 2012, Pages 3817-3826

  Madsen, Christine Vestergaard ^a,b   Steffensen, Karina Dahl ^a,b   Olsen, Dorte Aalund ^a   Waldstrøm, Marianne ^a   Søgaard, Charlotte Hasselholt ^c   Brandslund, Ivan ^a   Jakobsen, Anders ^a,b  

^a LILLEBAELT HOSPITAL   (Denmark)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^c AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

FGF2; Ovarian cancer; PDGF AA; PDGF BB; Prognostic factors; Serum

Indexed keywords

ANTINEOPLASTIC AGENT; ANTINEOPLASTIC METAL COMPLEX; FIBROBLAST GROWTH FACTOR 2; PLATELET DERIVED GROWTH FACTOR AA; PLATELET DERIVED GROWTH FACTOR BB;

ARTICLE; BLOOD SAMPLING; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER STAGING; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; DISEASE ASSOCIATION; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; OVARY CANCER; OVARY TUMOR; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TUMOR GROWTH; UPREGULATION;

FEMALE; FIBROBLAST GROWTH FACTOR 2; HUMANS; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; PLATELET-DERIVED GROWTH FACTOR; PROTO-ONCOGENE PROTEINS C-SIS; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 84866981538     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (59)

1. Folkman J: Role of angiogenesis in tumor growth and metastasis: Semin Oncol 29: 15-18, 2002.
2. Hanahan D and Weinberg RA: Hallmarks of cancer: the next generation: Cell 144: 646-674, 2011.
3. Folkman J: What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 82: 4-6, 1990.
4. Bergers G and Benjamin LE: Tumorigenesis and the angiogenic switch: Nat Rev Cancer 3: 401-410, 2003.
5. Hanahan D and Folkman J: Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis: Cell 86: 353-364, 1996. (Pubitemid 26272076)
6. Cao R, Brakenhielm E, Pawliuk R, Wariaro D, Post MJ, Wahlberg E, Leboulch P and Cao Y: Angiogenic synergism, vascular stability and improvement of hind-limb ischemia by a combination of PDGF-BB and FGF-2: Nat Med 9: 604-613, 2003. (Pubitemid 36597108)
7. Ferrara N and Kerbel RS: Angiogenesis as a therapeutic target: Nature 438: 967-974, 2005.
8. Kano MR, Morishita Y, Iwata C, Iwasaka S, Watabe T, Ouchi Y, Miyazono K and Miyazawa K: VEGF-A and FGF-2 synergistically promote neoangiogenesis through enhancement of endogenous PDGF-B-PDGFRbeta signaling: J Cell Sci 118: 3759-3768, 2005. (Pubitemid 41309422)
9. Dong J, Grunstein J, Tejada M, Peale F, Frantz G, Liang WC, Bai W, Yu L, Kowalski J, Liang X, Fuh G, Gerber HP and Ferrara N: VEGF-null cells require PDGFR alpha signaling-mediated stromal fibroblast recruitment for tumorigenesis: EMBO J 23: 2800-2810, 2004. (Pubitemid 39013552)
10. Brown AP, Citrin DE and Camphausen KA: Clinical biomarkers of angiogenesis inhibition: Cancer Metastasis Rev 27: 415-434, 2008.
11. Jain RK, Duda DG, Willett CG, Sahani DV, Zhu AX, Loeffler JS, Batchelor TT and Sorensen AG: Biomarkers of response and resistance to antiangiogenic therapy: Nat Rev Clin Oncol 6: 327-338, 2009.
12. Poon RT, Fan ST and Wong J: Clinical implications of circulating angiogenic factors in cancer patients: J Clin Oncol 19: 1207-1225, 2001. (Pubitemid 32176299)
13. Abdollahi A and Folkman J: Evading tumor evasion: Current concepts and perspectives of anti-angiogenic cancer therapy: Drug Resist Updat 13: 16-28, 2010.
14. Nugent MA and Iozzo RV: Fibroblast growth factor-2: Int J Biochem Cell Biol 32: 115-120, 2000.
15. Ornitz DM and Itoh N: Fibroblast growth factors: Genome Biol 2: 3005.1-3005.12, 2001.
16. Presta M, Dell'Era P, Mitola S, Moroni E, Ronca R and Rusnati M: Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis: Cytokine Growth Factor Rev 16: 159-178, 2005. (Pubitemid 40616114)
17. Turner N and Grose R: Fibroblast growth factor signalling: From development to cancer: Nat Rev Cancer 10: 116-129, 2010.
18. Pasieka Z, Stepien H, Komorowski J, Kolomecki K and Kuzdak K: Evaluation of the levels of bFGF, VEGF, sICAM-1, and sVCAM-1 in serum of patients with thyroid cancer: Recent Results Cancer Res 162: 189-194, 2003.
19. Rahbari NN, Reissfelder C, Muhlbayer M, Weidmann K, Kahlert C, Buchler MW, Weitz J and Koch M: Correlation of circulating angiogenic factors with circulating tumor cells and disease recurrence in patients undergoing curative resection for colorectal liver metastases: Ann Surg Oncol 18: 2182-2191, 2011.
20. Aigner A, Brachmann P, Beyer J, Jager R, Raulais D, Vigny M, Neubauer A, Heidenreich A, Weinknecht S, Czubayko F and Zugmaier G: Marked increase of the growth factors pleiotrophin and fibroblast growth factor-2 in serum of testicular cancer patients: Ann Oncol 14: 1525-1529, 2003. (Pubitemid 37304608)
21. Granato AM, Nanni O, Falcini F, Folli S, Mosconi G, De PF, Medri L, Amadori D and Volpi A: Basic fibroblast growth factor and vascular endothelial growth factor serum levels in breast cancer patients and healthy women: Useful as diagnostic tools? Breast Cancer Res 6: R38-R45, 2004.
22. Rykala J, Przybylowska K, Majsterek I, Pasz-Walczak G, Sygut A, Dziki A and Kruk-Jeromin J: Angiogenesis marker quantification in breast cancer and their correlation with clinicopathological prognostic variables: Pathol Oncol Res 17: 809-817, 2011.
23. Joensuu H, Anttonen A, Eriksson M, Makitaro R, Alfthan H, Kinnula V and Leppa S: Soluble syndecan-1 and serum basic fibroblast growth factor are new prognostic factors in lung cancer: Cancer Res 62: 5210-5217, 2002. (Pubitemid 35024592)
24. Ruotsalainen T, Joensuu H, Mattson K and Salven P: High pretreatment serum concentration of basic fibroblast growth factor is a predictor of poor prognosis in small cell lung cancer: Cancer Epidemiol Biomarkers Prev 11: 1492-1495, 2002. (Pubitemid 35340391)
25. Rasmuson T, Grankvist K, Jacobsen J and Ljungberg B: Impact of serum basic fibroblast growth factor on prognosis in human renal cell carcinoma: Eur J Cancer 37: 2199-2203, 2001. (Pubitemid 33001289)
26. Poon RT, Ng IO, Lau C, Yu WC, Fan ST and Wong J: Correlation of serum basic fibroblast growth factor levels with clinicopathologic features and postoperative recurrence in hepatocellular carcinoma: Am J Surg 182: 298-304, 2001. (Pubitemid 32918381)
27. Barton DP, Cai A, Wendt K, Young M, Gamero A and De CS: Angiogenic protein expression in advanced epithelial ovarian cancer: Clin Cancer Res 3: 1579-1586, 1997. (Pubitemid 27431566)
28. Le Page C, Ouellet V, Madore J, Hudson TJ, Tonin PN, Provencher DM and Mes-Masson AM: From gene profiling to diagnostic markers: IL-18 and FGF-2 complement CA125 as serum-based markers in epithelial ovarian cancer: Int J Cancer 118: 1750-1758, 2006. (Pubitemid 43376439)
29. Heldin CH and Westermark B: Mechanism of action and in vivo role of platelet-derived growth factor: Physiol Rev 79: 1283-1316, 1999. (Pubitemid 29473317)
30. Westermark B, Siegbahn A, Heldin CH and Claesson-Welsh L: B-Type receptor for platelet-derived growth factor mediates a chemotactic response by means of ligand-induced activation of the receptor protein-tyrosine kinase: Proc Natl Acad Sci USA 87: 128-132, 1990.
31. Forsberg K, Valyi-Nagy I, Heldin CH, Herlyn M and Westermark B: Platelet-derived growth factor (PDGF) in oncogenesis: development of a vascular connective tissue stroma in xenotransplanted human melanoma producing PDGF-BB: Proc Natl Acad Sci USA 90: 393-397, 1993. (Pubitemid 23028868)
32. Pietras K and Ostman A: Hallmarks of cancer: interactions with the tumor stroma: Exp Cell Res 316: 1324-1331, 2010.
33. Schmitt J and Matei D: Platelet-Derived Growth Factor Pathway Inhibitors in Ovarian Cancer: Clinical Ovarian Cancer 1: 120-126, 2008.
34. Yu J, Moon A and Kim HR: Both platelet-derived growth factor receptor (PDGFR)-alpha and PDGFR-beta promote murine fibroblast cell migration: Biochem Biophys Res Commun 282: 697-700, 2001. (Pubitemid 32924612)
35. Hellberg C, Ostman A and Heldin CH: PDGF and vessel maturation: Recent Results Cancer Res 180: 103-114, 2010.
36. Lindahl P, Johansson BR, Leveen P and Betsholtz C: Pericyte loss and microaneurysm formation in PDGF-B-deficient mice: Science 277: 242-245, 1997. (Pubitemid 27446080)
37. Bran B, Bran G, Hormann K, and Riedel F: The platelet-derived growth factor receptor as a target for vascular endothelial growth factor-mediated anti-angiogenetic therapy in head and neck cancer: Int J Oncol 34: 255-261, 2009.
38. Mantur M, Snarska J, Sidorska A, Ostrowska H, Kruszewska-Wnorowska K and Wojszel J: Changes in PDGF concentration in surgically treated colorectal carcinoma: Adv Med Sci 53: 37-41, 2008.
39. Krzystek-Korpacka M, Diakowska D, Gamian A and Matusiewicz M: Increase in serum platelet-derived growth factor (PDGF)-BB reflects lymph node involvement in esophageal cancer patients independently from platelet count: Exp Oncol 33: 140-144, 2011.
40. Filiberti R, Marroni P, Neri M, Ardizzoni A, Betta PG, Cafferata MA, Canessa PA, Puntoni R, Ivaldi GP and Paganuzzi M: Serum PDGF-AB in pleural mesothelioma: Tumour Biol 26: 221-226, 2005.
41. Rahbari NN, Schmidt T, Falk CS, Hinz U, Herber M, Bork U, Buchler MW, Weitz J and Koch M: Expression and prognostic value of circulating angiogenic cytokines in pancreatic cancer: BMC Cancer 11: 286-2011.
42. Pasanisi P, Venturelli E, Morelli D, Fontana L, Secreto G and Berrino F: Serum insulin-like growth factor-I and platelet-derived growth factor as biomarkers of breast cancer prognosis: Cancer Epidemiol Biomarkers Prev 17: 1719-1722, 2008.
43. Yamamoto S, Tsuda H, Takano M, Kita T, Kudoh K, Furuya K, Tamai S and Matsubara O: Expression of platelet-derived growth factors and their receptors in ovarian clear-cell carcinoma and its putative precursors: Mod Pathol 21: 115-124, 2008. (Pubitemid 351172160)
44. Wilczynski SP, Chen YY, Chen W, Howell SB, Shively JE and Alberts DS: Expression and mutational analysis of tyrosine kinase receptors c-KIT, PDGFRα, and PDGFRβ in ovarian cancers: Hum Pathol 36: 242-249, 2005. (Pubitemid 40404007)
45. Schmandt RE, Broaddus R, Lu KH, Shvartsman H, Thornton A, Malpica A, Sun C, Bodurka DC and Gershenson DM: Expression of c-ABL, c-KIT, and platelet-derived growth factor receptor-beta in ovarian serous carcinoma and normal ovarian surface epithelium: Cancer 98: 758-764, 2003. (Pubitemid 36959272)
46. Matei D, Emerson RE, Lai YC, Baldridge LA, Rao J, Yiannoutsos C and Donner DD: Autocrine activation of PDGFRα promotes the progression of ovarian cancer: Oncogene 25: 2060-2069, 2006.
47. Lassus H, Sihto H, Leminen A, Nordling S, Joensuu H, Nupponen NN and Butzow R: Genetic alterations and protein expression of KIT and PDGFRA in serous ovarian carcinoma: Br J Cancer 91: 2048-2055, 2004. (Pubitemid 40136610)
48. Henriksen R, Funa K, Wilander E, Backstrom T, Ridderheim M and Oberg K: Expression and prognostic significance of platelet-derived growth factor and its receptors in epithelial ovarian neoplasms: Cancer Res 53: 4550-4554, 1993. (Pubitemid 23304378)
49. Dabrow MB, Francesco MR, McBrearty FX and Caradonna S: The effects of platelet-derived growth factor and receptor on normal and neoplastic human ovarian surface epithelium: Gynecol Oncol 71: 29-37, 1998. (Pubitemid 28492389)
50. Apte SM, Bucana CD, Killion JJ, Gershenson DM and Fidler IJ: Expression of platelet-derived growth factor and activated receptor in clinical specimens of epithelial ovarian cancer and ovarian carcinoma cell lines: Gynecol Oncol 93: 78-86, 2004. (Pubitemid 38429552)
51. Matei D, Kelich S, Cao L, Menning N, Emerson RE, Rao J, Jeng MH and Sledge GW: PDGF BB induces VEGF secretion in ovarian cancer: Cancer Biol Ther 6: 1951-1959, 2007. (Pubitemid 351590409)
52. Fattaneh A, Tavassoli and Devilee P: Pathology & Genetics. Túmors of the Breast and Female Genital Organs. WHO Classification of Tumors: 2003.
53. Shimizu Y, Kamoi S, Amada S, Akiyama F and Silverberg SG: Toward the development of a universal grading system for ovarian epithelial carcinoma: Testing of a proposed system in a series of 461 patients with uniform treatment and follow-up: Cancer 82: 893-901, 1998. (Pubitemid 28104169)
54. Kurman RJ and Shih I: The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory: Am J Surg Pathol 34: 433-443, 2010.
55. du BA, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I and Pfisterer J: Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO): Cancer 115: 1234-1244, 2009.
56. Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL and Montz FJ: Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: A meta-analysis: J Clin Oncol 20: 1248-1259, 2002. (Pubitemid 34177431)
57. Stuart GC, Kitchener H, Bacon M, duBois A, Friedlander M, Ledermann J, Marth C, Thigpen T, and Trimble E: 2010 Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: report from the Fourth Ovarian Cancer Consensus Conference: Int J Gynecol Cancer 21: 750-755, 2011.
58. Krzystek-Korpacka M, Neubauer K and Matusiewicz M: Platelet-derived growth factor-BB reflects clinical, inflammatory and angiogenic disease activity and oxidative stress in inflammatory bowel disease: Clin Biochem 42: 1602-1609, 2009.
59. Zimmermann R, Koenig J, Zingsem J, Weisbach V, Strasser E, Ringwald J and Eckstein R: Effect of specimen anticoagulation on the measurement of circulating platelet-derived growth factors: Clin Chem 51: 2365-2368, 2005. (Pubitemid 41692585)